Floatz logo

Inno-206

HBV

Shandong Cancer Hospital and InstitutePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the HBV cohort.

Asset / SponsorPhaseRating
tenofovir
Ruijin Hospital
Phase 4BB
Sorafenib
Mina Alpha Limited
Phase 2B
sb-497115-gr
GlaxoSmithKline
Phase 3B
Ipilimumab
Universita di Verona
Phase 2CCC
Carboplatin
Universita di Verona
Phase 2CCC

View all 11 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →